Exercise Snacks Are Feasible to Perform in the Real World and Improve Physical Capacity for Adults Living With Non-Insulin Treated Type 2 Diabetes: A Randomised Trial.

Diabetes Obes MetabJul 25, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Fiona J Babir, Alexis Marcotte-Chénard, Roderick E Sandilands et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the feasibility and efficacy of a 12-week remotely-delivered exercise snacks (ES) intervention in 69 adults with non-insulin treated type 2 diabetes. The study found that while adherence was similar between the ES and mobility/stretching groups, the ES group showed a significant improvement in sit-to-stand capacity, with an effect estimate of 1.9 repetitions.

Key findings

  • Weekly adherence was high, with an estimated mean of 18 bouts for both groups.
  • Exercise snacks resulted in a higher rating of perceived exertion (5.7) compared to the control group (2.0).
  • The ES group had a greater improvement in sit-to-stand capacity, with an effect estimate of 1.9 repetitions.

Why it matters

The findings suggest that exercise snacks can be a practical and effective strategy to enhance physical capacity in adults with type 2 diabetes, potentially improving their overall health and quality of life.

Source

PubMed · PMID 42502209Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.